Are we close to targeted treatments for Huntington’s disease? COMMENT


Authors: doc. MUDr. Matej Škorvánek;  Phd
Authors‘ workplace: Neurologická klinika, LF UPJŠ a UNLP ;  Košice
Published in: Cesk Slov Neurol N 2020; 83/116(3): 242
Category:


Sources

1. Frank S, Testa CM, Stamler D et al. Effect of deutetrabenazine on chorea among patients with huntington disease a randomized clinical trial. Jama J Am Med Assoc 2016; 316 (1): 40–50. doi: 10.1001/jama.2016.8655.

2. Mestre TA. Recent advances n the therapeutic development for Huntington disease. Park Relat Disord 2019; 59: 125–130. doi: 10.1016/j.parkreldis.2018.12.003.

3. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al. Targeting Huntingtin expression in patients with Huntington‘s disease. N Engl J Med 2019; 380 (24): 2307–2316. doi: 10.1056/NEJMoa1900907.

4. Investigators HSGRH. Safety, tolerability, and efficacy of PBT2 in Huntington‘s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015; 14 (1): 39–47. doi: 10.1016/S1474-4422 (14) 70262-5.

5. Reilmann R, Squitieri F, Priller J et al. Safety and tolerability of selisistat for the treatment of huntington‘s disease: results from a randomised, double-blind, placebo-controlled phase II trial. J Neurol Neurosurg Psychiatr 2014; 82 (10 Suppl): A102.

6. A. Biotech. [online]. Dostupné z URL: https: //www.activebiotech.com/en/media/ pressreleases/?id=2208124&date=1533024900.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 3

2020 Issue 3

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account